1. International Labour Organization, World Health Organization. Press release: Number of work-related accidents and illnesses continues to increase: ILO and WHO join in call for prevention strategies. Issued April 28, 2005.
2. Brodeur P. Asbestos and Enzymes. New York: Ballantine, 1972.
3. Brodeur P. Expendable Americans. New York: Viking, 1973.
4. Brodeur P. Outrageous Misconduct: The Asbestos Industry on Trial. New York: Pantheon, 1985.
5. Castleman B. Asbestos: Medical and Legal Aspects, 5th ed. New York: Aspen, 2005.
6. Ozonoff D. Failed warnings: Asbestos-related disease and industrial medicine In: Bayer R, ed. Case Studies in the Politics of Professional Responsibility. New York: Oxford University Press, 1988:139–218.
7. Schneider A, McCumber D. An Air That Kills: How the Asbestos Poisoning of Libby, Montana, Uncovered a National Scandal. New York: Putnam, 2004.
8. Egilman D, Fehnel C, Bohme SR. Exposing the ‘‘myth’’ of ABC, ‘‘anything but chrysotile’’: A critique of the Canadian asbestos mining industry and McGill University chrysotile studies. Am J Ind Med. 2003;44(5):540–57.
9. Tweedale G. Magic Mineral to Killer Dust. New York: Oxford University Press, 2000.
10. McCulloch J. Asbestos: Its Human Cost. New York: University of Queensland Press, 1986.
11. Frist W. Asbestos litigation crisis (Senate proceedings, November 22, 2003). Congressional Record. 2003:S15514–S15515.
12. Annual report of Her Majesty’s Lady Inspectors. In Annual Report of the Chief Inspector of Factories and Workshops for the Year 1898. Part II: Reports. London: Her Majesty’s Stationery Office, 1898:172.
13. Hoffman FL. Mortality from respiratory diseases from dusty trades (inorganic dusts) [bulletin]. U.S. Department of Labor, Bureau of Labor Statistics. Whole no. 231, Industrial Accidents and Hygiene Series no. 17. June 1918.
14. Cherniak M. The Hawk’s Nest Incident: America’s Worst Industrial Disaster. New Haven, CT: Yale University Press, 1986.
15. Trudeau Institute History. Available at: http://www.trudeauinstitute.org/info/history/history.htm. Accessed in June 2007.
16. Dreessen WC, Dallavalle JM, Edwards TI et al. A study of asbestosis in the asbestos textile industry. U.S. Treasury Department, Public Health Service. Public Health bulletin no. 241. August 1938.
17. Industrial Hygiene Foundation of America. Report of preliminary dust investigation for Asbestos Textile Institute. June 18, 1947. Pittsburgh, PA.
18. Brown V. The management viewpoint: Discussion. In: Vorwald AJ, ed. Pneumoconiosis: Beryllium, Bauxite Fumes, Compensation. New York: Hoeber, 1950;567–72.
19. Hueper, W. Occupational Tumors and Allied Diseases. Baltimore, MD: Thomas, 1942.
20. Asbestosis and cancer of the lung. [Editorial]. JAMA. 1949;140(9):1219–20.
21. Conklin G. Cancer and the environment. Sci Am. 1949;180(1):11–15.
22. Proctor RN. The Nazi War on Cancer. Princeton, NJ: Princeton University Press, 1999.
23. Vorwald AJ, Durkan TM, Pratt PC. Experimental studies of asbestosis. AMA Arch Ind Hyg Occup Med. 1951;3(1):1–43.
24. Asbestos Textile Institute Air Hygiene and Manufacturing Committee. Meeting minutes. March 7, 1957.
25. Pritchard J (Pathologist, Wayne State University College of Medicine, Department of Industrial Medicine and Hygiene). Pathology report: William Cooling (Autopsy conducted at Montreal General Hospital, January 1949).
26. Smoking and Health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. U.S. Department of Health Education and Welfare: Public Health Service, 1964. Public Health Service publication no. 1103.
27. Selikoff IJ, Churg J, eds. Biological effects of asbestos. Ann NY Acad Sci. 1965;132(1):1–766.
28. Brodeur P. The magic mineral. New Yorker. October 12, 1968.
29. Cadwalader, Wickersham, and Taft (lawyers for Asbestos Textile Institute). Letter to Selikoff I. October 26, 1964.
30. About the speaker: Matthew M. Swetonic. Addendum to meeting minutes for Asbestos Textile Institute general meeting. Key Bridge Marriott, Arlington, VA, June 7, 1973.
31. Hill and Knowlton, Inc. Division of Scientific, Technical, and Environmental Affairs; ca. 1989. Available at: http://www.defendingscience.org/upload/HK_1989.pdf. Accessed in December 2007.
32. Hill and Knowlton, Inc. Division of Scientific, Technical, and Environmental Affairs. Case study: Asbestos and human health; ca. 1989. Available at: http://www.defendingscience.org/upload/HK_1989.pdf. Accessed in December 2007.
33. Filteau PA (General Manager, Quebec Asbestos Mining Association [QAMA]). Special winter meeting, Grand Bahama Hotel and Country Club. January 31, 1968: 8.
34. Selikoff IJ, Hammond E, Churg J. Asbestos exposure, smoking, and neoplasia. JAMA. 1968;204(2):106–12.
35. Evans EE (director, Medical Division, Chambers Works) on behalf of Brothers WC (manager, Chambers Works). Letter to Mangelsdorff A (Calco Chemical Co.). June 18, 1947. Available at: http://www.defendingscience.org/upload/Evans_1947.pdf. Accessed in December 2007.
36. Scott TS. Carcinogenic and Chronic Toxic Hazards of Aromatic Amines. New York: Elsevier, 1962.
37. Norton TH. Dyestuffs for American Textile and Other Industries. U.S. Department of Commerce, Bureau of Foreign and Domestic Commerce Special Agents Series, no. 96, 1915.
38. National Academy of Engineering. Technology and Environment. Washington, DC: National Academy Press, 1989.
39. Dietrich H, Dietrich B. Ludwig Rehn (1849–1930). Pioneering findings on the aetioliogy of bladder cancers. World J Urol. 2000;19:151–53.
40. Hueper W. Occupational and Environmental Cancers of the Urinary System. New Haven, CT: Yale University Press, 1969.
41. International Labour Organization. Cancer of the Bladder among Workers in Aniline Factories. Studies and Reports Series F, no. 1. February 1921.
42. U.S. Tariff Commission. Dyes. (Prepared in response to requests from the Committee on Finance of the U.S. Senate and the Committee on Ways and Means of the House of Representatives). War Changes in Industry Series, report no. 19, 1946.
43. DuPont, the Autobiography of an American Enterprise. New York: Scribner, 1952.
44. Hounshell D, Smith JK. Jr. Science and Corporate Strategy: Du Pont R&D, 1902–1980. New York: Cambridge University Press, 1988.
45. Smith DT (supervisor, Protection Division). Letter to Queener JS (manager, Safety and Fire Protection Division). Subject: History of beta-naphthylamine manufacture: Chamber Works. September 22, 1958. Available at: http://www.defendingscience.org/upload/Smith_1958.pdf. Accessed in December 2007.
46. Michaels D. Waiting for the body count: Corporate decision making and bladder cancer in the U.S. dye industry. Med Anthro Q. 1988; 2:215–232.
47. Michaels D. When science isn’t enough: Wilhelm Hueper, Robert A.M. Case and the limits of scientific evidence in preventing occupational bladder cancer. Int J Occup Environ Health. 1995;1:278–288.
48. Washburn V. Abstract of discussion. JAMA. 1936;107:1438–39.
49. Wignall TH. Incidence of disease of the bladder in workers in certain chemicals. BMJ. 1929;2:291–93.
50. Agran L. The Cancer Connection. Boston, MA: Houghton Mifflin, 1977.
51. Hueper WC. Wilhelm Hueper’s autobiography. Unpublished manuscript.
52. Hueper WC, Wiley FH, Wolfe HD. Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. J Ind Hyg Toxicol. 1938;20:46–84.
53. Evans E. Causative agents and protective measures in the anilin tumor of the bladder. J Urol. 1936;38:212–15.
54. Agran L. Interview with Dr. Wilhelm C. Hueper, MD; December 1975. In: Breslow L, ed. A History of Cancer Control in the United States, 1946–1971. DHEW publication no. (NIH) 79–1519, 1979.
55. Bent S. Tetraethyl lead fatal to makers. New York Times. June 22, 1925:3.
56. Markowitz G, Rosner D. Deceit and Denial: The Deadly Politics of Industrial Pollution. Berkeley, CA: University of California Press, 2002.
57. Schwartz BS, Bolla KI, Stewart W et al. Decrements in neurobehavioral performance associated with mixed exposure to organic and inorganic lead. Am J Epidemiol. 1993;137(9):1006–21.
58. Schwartz BS, Stewart WF, Bolla KI et al. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology. 2000;55:1144–50.
59. Otto GB. Operation of new plant/chronological history: Manufacture of beta napthylamine. Unpublished report. April 13, 1953. Available at: http://www.defendingscience.org/upload/Otto_1953.pdf. Accessed in December 2007.
60. Weiss RJ. Email to Fayerweather WE and Karns E. October 25, 1991.
61. Epstein S. Presentation of the first award of the Society for Occupational and Environmental Health to Dr. Wilhelm C. Hueper. Ann NY Acad Sci. 1975;271:457–59.
62. Case R. The misbegotten camel. Unpublished manuscript. 1983.
63. Case R. Tumors of the urinary tract as an occupational disease in several industries. Ann Royal College Surgery. 1966;39:213–35.
64. Case RAM. Incidence of death from tumours of the urinary bladder. Br J Prev Soc Med. 1953;7(1):14–19.
65. Case R, Hosker, M, McDonald D et al.Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry: Part 1: The role of aniline, benzidine, alphanaphthylamine, and beta-naphthylamine. British J Ind Med. 1954;11:75–96.
66. Case RAM, Hosker ME. Tumour of the urinary bladder as an occupational disease in the rubber industry in England and Wales. British J Prev Soc Med. 1954;48:39–50.
67. Ward E, Carpenter A, Markowitz S et al. Excess number of bladder cancers in workers exposed to ortho-toluidine and aniline. J Natl Cancer Inst. 1991;83(7):501– 06.
68. Gehrmann GH, Foulger JH, Fleming AJ. Occupational tumours of the bladder. Paper presented at Ninth International Congress on Industrial Medicine, 1948. London, 1949.
69. Case RAM (Chester Beatty Research Institute, London). Letter to the Editor (Washington Post). July 30, 1979. Printed in Corporate Criminal Liability Hearing Report for Sessions 1 and 2. U.S. House of Representatives (96th Cong.), Committee on the Judiciary, Subcommittee on Crime. 71:101– 03. Washington, DC: U.S. Government Printing Office, 1981.
70. Castleman B. DuPont’s record in business ethics: Another view. Washington Post. July 15, 1979:E4.
71. Spitz S, Maguigan WH, Dobriner K. The carcinogenic action of benzidine. Cancer. 1950;3(5):789–804.
72. Ferber KH, Hill WJ, Cobb DA. An assessment of the effect of improved working conditions on bladder tumor incidence in a benzidine manufacturing facility. Am Ind Hyg Assoc J. 1976;37(1):61–68.
73. Johnson W, Parnes W. Beta-naphthylamine and benzidine: Identification of groups at high risk of bladder cancer. Ann NY Acad Sci. 1979;329:277–84.
74. Scott TS. The incidence of bladder tumours in a dyestuffs factory. Br J Ind Med. 1952;9(2):127–32.
75. Bingham E. Personal communication, April 26, 1988.
76. Zavon M, Hoegg U, Bingham E. Benzidine exposure as a cause of bladder tumors. Arch Environ Health. 1973;27(1):1–7.
77. Mancuso T, El-Attar A. Cohort study of workers exposed to betanaphthylamine and benzidine. J Occup Med. 1967;9:277–85.
78. Fleming A, D’Alonzo C, Zapp J. Modern Occupational Medicine. Philadelphia: Lea and Febiger, 1954.
79. Mason T, Prorock P, Neeld W et al. Screening for bladder cancer at the DuPont Chamber Works: Initial findings. J Occup Med. 1986;28:1011–16.
80. Temkin IS. Industrial Bladder Carcinogenesis. New York: Pergamon, 1963.
81. Stern FB, Murthy LI, Beaumont JJ et al. Notification and risk assessment for bladder cancer of a cohort exposed to aromatic amines. III. Mortality among workers exposed to aromatic amines in the last beta-naphthylamine manufacturing facility in the United States. J Occup Med. 1985;27(7):495–500.
